Skip to main content
TipRanks
Go Ultimate75% OFF

Polylite Taiwan Co., Ltd. (1813) AI Stock Analysis

TW:1813

Polylite Taiwan Co., Ltd.

(TPEx:1813)

Select Model
Rating:49Neutral
Price Target:TWD 10.00â–¼(-4.31% Downside)
Action:initiatedcoverage
Date:11/10/26

The score is primarily constrained by severe revenue contraction, persistent losses, and a bearish technical trend. The relatively solid balance sheet and positive cash flow provide meaningful support, but the elevated P/E and lack of dividend yield limit the investment case.

Positive Factors
Moderate LeverageModerate leverage gives Polylite a stronger financial foundation than a highly indebted peer and preserves some flexibility to manage cyclical demand. Debt levels are not extreme, reducing the risk that interest or refinancing needs will overwhelm operations during the earnings downturn.
Negative Factors
Severe Revenue DeclineThe sharp two-year top-line deterioration indicates substantial pressure on demand or pricing and materially reduces the scale of the business. Unless revenue stabilizes, lower volume will make fixed costs harder to absorb and constrain the company’s ability to rebuild sustainable earnings.

Polylite Taiwan Co., Ltd. (1813) vs. SPDR S&P 500 ETF (SPY)

-30%-20%-10%0%10%20%TW:1813-20.53%SPY+14.28%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
TWD 478.01M
Dividend Yield
―
Average Volume (3M)
19.77K
Price to Earnings (P/E)
61.1
Beta (1Y)
0.23
Revenue Growth
-6.91%
EPS Growth
―
Country
TW
Employees
149
Sector
General
Sector Strength
55
Industry
Semiconductors

Polylite Taiwan Co., Ltd. Business Overview & Revenue Model

Company Description

Polylite Taiwan Co., Ltd. is an international enterprise engaged in the fabrication, refinement, worldwide trade, and retail of a diverse selection of optical lenses, precision optical devices, and medical instruments. A key part of its product line...

Polylite Taiwan Co., Ltd. Financial Statement Overview

Summary

Financial performance is below average: the income statement score is weak at 15 due to severe revenue decline and persistent losses. A solid balance sheet and positive operating and free cash flow provide support, with balance sheet and cash flow scores of 75 and 60.

Income Statement

15Very Negative

Balance Sheet

75Positive

Cash Flow

60Neutral
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue287.69M304.32M309.91M360.45M362.05M451.13M
Gross Profit-47.72M-52.32M-59.80M-3.93M-22.26M19.58M
EBITDA-48.33M-1.81M-54.00M-11.38M11.54M45.52M
Net Income7.50M-47.94M-29.30M11.20M6.71M-13.13M
Balance Sheet
Total Assets968.25M931.76M1.01B1.05B1.14B1.26B
Cash, Cash Equivalents and Short-Term Investments146.40M138.21M119.04M150.27M210.44M305.97M
Total Debt238.04M217.53M241.96M204.99M251.25M323.77M
Total Liabilities304.44M270.75M302.59M276.56M315.79M426.21M
Stockholders Equity693.34M684.54M723.73M774.95M811.94M813.72M
Cash Flow
Free Cash Flow61.93M36.53M30.39M36.75M16.05M60.11M
Operating Cash Flow67.64M46.81M35.20M46.22M31.93M78.68M
Investing Cash Flow-16.24M-10.05M-67.63M-9.11M-14.79M-19.50M
Financing Cash Flow-12.73M-18.84M13.48M-97.52M-99.45M29.27M

Polylite Taiwan Co., Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

TW:1813 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
TW:1813TW:181349NeutralTWD 478.01M61.08――-6.91%―

* General Sector Average

Performance Comparison

-60%-40%-20%0%20%TW:1813TW:4115TW:4170TW:6660TW:6999TW:7726Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
TW:1813 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
TW:1813Polylite Taiwan Co., Ltd.10.45-2.75-20.83%
TW:4115Sunder Biomedical Tech. Co., Ltd.6.97-1.43-17.02%
TW:4170Vectorite Biomedical, Inc.11.00-2.60-19.12%
TW:6660HMD Biomedical, Inc.12.70-11.05-46.53%
TW:6999Han Biomedical, Inc.24.45-6.02-19.75%
TW:7726CARILEX MEDICAL INC.32.15-3.95-10.94%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 09, 2026